<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Treatment, prognosis, and prevention</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Treatment, prognosis, and prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Treatment, prognosis, and prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Talmadge E King, Jr, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kevin R Flaherty, MD, MS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 05, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hypersensitivity pneumonitis (HP), also called extrinsic allergic alveolitis, is a syndrome characterized by diffuse inflammation of lung parenchyma and airways in response to the inhalation of antigens to which the patient has been previously sensitized. Numerous inciting agents have been described including, but not limited to, agricultural dusts, bioaerosols, and certain reactive chemical species. (See  <a class="medical medical_review" href="/z/d/html/4309.html" rel="external">"Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Epidemiology, causes, and pathogenesis"</a>.)</p><p>Both environmental and host factors are involved in the production of the HP syndromes, so management theoretically can involve modification of the environment or of the host immune response [<a href="#rid1">1</a>]. As the pathogenesis of HP is incompletely understood, emphasis on environmental control remains the cornerstone of therapy [<a href="#rid2">2</a>]. The treatment, prognosis, and prevention of HP will be reviewed here. The epidemiology, causes, clinical manifestations, and diagnosis of HP are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/4309.html" rel="external">"Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Epidemiology, causes, and pathogenesis"</a> and  <a class="medical medical_review" href="/z/d/html/4313.html" rel="external">"Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Antigen avoidance is the cornerstone of treatment for symptomatic hypersensitivity pneumonitis and usually results in regression of disease [<a href="#rid1">1,3-5</a>]. Additional treatment may be required in more severe or progressive disease. The best studied forms of HP are farmer's lung and bird fancier’s lung; treatment of other types of HP largely is extrapolated from the experiences in these populations. </p><p class="headingAnchor" id="H8"><span class="h2">Antigen avoidance</span><span class="headingEndMark"> — </span>Patients with HP should be encouraged to completely avoid (preferred) ongoing exposure to the provocative antigen(s) [<a href="#rid1">1,3-6</a>]. Patients with progression of disease in the context of ongoing exposure should be advised in the strongest terms to avoid the antigen completely and by whatever means necessary [<a href="#rid5">5,7-9</a>].</p><p>As an exception, some patients, such as those with farmers’ lung who have prompt resolution of initial symptoms, may do well despite continued low level exposure, making it difficult to determine the degree to which antigen avoidance is required in such patients. The risk of recurrence is unclear in this setting, and drastic measures to avoid inciting antigens may not always be indicated [<a href="#rid10">10-13</a>]. </p><p>Antigen avoidance depends on identification of the antigen(s) responsible for HP in the individual patient  (<a class="graphic graphic_table graphicRef55505" href="/z/d/graphic/55505.html" rel="external">table 1</a>) (see  <a class="medical medical_review" href="/z/d/html/4309.html" rel="external">"Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Epidemiology, causes, and pathogenesis"</a>). A standardized questionnaire which elicits exposure characteristics is helpful in increasing diagnostic confidence of chronic HP [<a href="#rid14">14</a>]. Sometimes, antigen avoidance is straightforward, such as removing birds or feather bedding from the household, avoiding hot tubs and water flume slides, or sterilizing humidifiers and vaporizers [<a href="#rid1">1,3,15</a>]. For other patients, complete avoidance may require relocation to a new job or home, although such drastic steps may not guarantee improvement. Additional measures to minimize ongoing antigenic exposure are described below. (See <a class="local">'Mitigation and prevention'</a> below and  <a class="medical medical_review" href="/z/d/html/4309.html" rel="external">"Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Epidemiology, causes, and pathogenesis"</a>.)</p><p>Farmer's lung poses particular problems because of the emotional and financial ramifications of leaving the farm environment. While a change of employment and residence may be necessary in persons with severe disease, several studies show that most farmers with HP do not progress clinically even if they do not modify their employment [<a href="#rid10">10,11,16</a>].</p><p>Persons with bird fancier's lung are frequently reluctant to give up their birds. Even after removal of the birds and environmental cleanup, recovery is not assured because high levels of bird antigens can be detected in the home environment for prolonged periods of time [<a href="#rid17">17</a>]. </p><p>In addition to treatment of the index patient, antigen identification and avoidance are important in preventing sensitization of co-workers and family members. </p><p class="headingAnchor" id="H3265558594"><span class="h2">Acute HP with minimal or transient symptoms</span><span class="headingEndMark"> — </span>For most patients with acute HP and mild or intermittent respiratory symptoms, we advise complete antigen avoidance (see <a class="local">'Antigen avoidance'</a> above), rather than oral glucocorticoids. Antigen avoidance, such as removal of feather bedding, cleaning a contaminated humidifier, or workplace mitigation, is usually sufficient treatment. We re-evaluate patients after 6 to 12 weeks to ensure improvement in symptoms and lung function, or sooner if symptoms are not improving. </p><p class="headingAnchor" id="H3771791944"><span class="h2">Acute or subacute HP with persistent symptoms</span><span class="headingEndMark"> — </span>For patients with acute or subacute HP and recurrent or persistent symptoms and lung function impairment, avoidance of causative antigens remains the most important intervention (see <a class="local">'Antigen avoidance'</a> above). Addition of oral glucocorticoids can accelerate initial recovery. </p><p class="headingAnchor" id="H9"><span class="h3">Glucocorticoids</span><span class="headingEndMark"> — </span>Based upon experience from observational studies of farmer's lung and bird fancier's lung [<a href="#rid4">4,18-20</a>], we suggest a short course of oral glucocorticoids in patients with subacute HP and moderate respiratory impairment to accelerate improvement. However, the long-term outcome appears unchanged by glucocorticoid treatment.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient selection</strong> – Glucocorticoids are usually prescribed for patients with persistent symptoms (eg, dyspnea, cough, fatigue, weight loss), abnormal lung function tests (eg, FVC or DLCO &lt;80 percent predicted), hypoxemia, or radiographic evidence of extensive lung involvement [<a href="#rid21">21,22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and duration</strong> – Therapy is usually initiated with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, 0.5 mg/kg per day (up to 30 mg per day), given as a single dose each morning [<a href="#rid1">1,4</a>], although dose and duration have not been formally studied. This dose is maintained for one to two weeks and then tapered over the next two to four weeks. </p><p></p><p class="bulletIndent1">Maintenance doses are not usually required, particularly if the patient has been removed from exposure. Inhaled glucocorticoids (eg, nebulized <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a>) may be effective in treating or preventing recurrence, but this approach has not been well studied [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Evidence in favor of glucocorticoid therapy comes from studies such as the following:</p><p></p><p class="bulletIndent1">A trial of 36 persons with acute farmer's lung randomly assigned patients to eight weeks of treatment with either <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> or placebo [<a href="#rid19">19</a>]. After one month, there was a significant improvement in diffusing capacity for carbon monoxide (DLCO) in the prednisolone-treated group, but no statistically significant differences in forced vital capacity (FVC), forced expiratory volume in one second (FEV<sub>1</sub>), or DLCO were found after that time until follow-up was terminated at five years.</p><p></p><p class="bulletIndent1">One study of 93 patients with farmer's lung compared patients treated with glucocorticoids for 4 or 12 weeks with a group of control patients treated only with antigen avoidance [<a href="#rid18">18</a>]. Symptom resolution was more rapid among the glucocorticoid-treated groups, but no differences were noted in the course of disease or lung function among the three groups after six months. The 12 week glucocorticoid regimen offered no advantage over the four week regimen. Limitations of this report are that the nonglucocorticoid-treated group had less severe disease and the study was not blinded.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Systemic glucocorticoids cause a variety of side effects, and may not be tolerated by some patients. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p></p><p class="bulletIndent1">An additional concern is that glucocorticoid treatment may lead to an improved sense of well-being, causing the patient to be less stringent about measures to limit future antigen exposure [<a href="#rid24">24</a>].</p><p></p><p class="headingAnchor" id="H2969758475"><span class="h2">Chronic fibrotic HP</span><span class="headingEndMark"> — </span>The optimal management of chronic fibrotic HP is not well-established because of a paucity of clinical trial data. In the absence of such data, the following is a practical approach based on clinical experience and expert opinion [<a href="#rid3">3,4</a>].</p><p class="headingAnchor" id="H3752681898"><span class="h3">Do not neglect antigen avoidance</span><span class="headingEndMark"> — </span>For patients with chronic or fibrotic HP, identification and avoidance of culprit antigens are associated with improved survival in several observational studies [<a href="#rid1">1,3,7,25-27</a>]. For example, in one cohort of 377 patients with fibrotic HP, combined suspected antigen identification and avoidance was associated with greatly improved long-term transplant-free survival (approximately 20 versus 40 percent at five years, adjusted hazard ratio [HR] 0.47, 95% CI 0.31-0.71) [<a href="#rid27">27</a>]. Conversely, patients with suspected antigens without avoidance or with unidentifiable antigens demonstrated a similar increased risk of mortality (adjusted HR 2.22 and 2.09, respectively) compared with the antigen-avoidant group. In a separate study, patients with chronic bird-related HP were more likely to deteriorate over time when exposed to higher amounts of avian antigen, while those exposed to lower amounts were more likely to have stable disease [<a href="#rid7">7</a>]. (See <a class="local">'Antigen avoidance'</a> above.)</p><p class="headingAnchor" id="H3048241583"><span class="h3">Supportive care</span><span class="headingEndMark"> — </span>Supportive care should be provided given the chronicity of disease and includes smoking cessation, seasonal influenza and pneumococcal vaccinations, pulmonary rehabilitation, and supplemental oxygen as needed. (See  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">"Seasonal influenza vaccination in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1463.html" rel="external">"Pulmonary rehabilitation"</a> and  <a class="medical medical_review" href="/z/d/html/1445.html" rel="external">"Long-term supplemental oxygen therapy"</a>.)</p><p class="headingAnchor" id="H2224714779"><span class="h3">Glucocorticoids</span><span class="headingEndMark"> — </span>Based on expert opinion and observational data from studies of farmer's lung and bird fancier's lung, we suggest a trial of oral glucocorticoids for patients with chronic HP [<a href="#rid3">3,18-20</a>]. The usual initial dose is the equivalent of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 0.5 mg/kg per day (up to 30 mg per day) for four to eight weeks, followed by tapering to 10 to 20 mg per day by three months [<a href="#rid3">3,28</a>]. We use the following features to help decision-making, although this approach is based on clinical experience rather than trial data [<a href="#rid3">3</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with inflammatory features</strong> – Patients with inflammatory features, such as ground-glass opacities on high-resolution computed tomography (HRCT), bronchoalveolar lavage (BAL) lymphocytosis (eg, &gt;20 percent), and/or histopathologic cellular interstitial pneumonia or granulomas, are more likely to experience improvement with glucocorticoid therapy [<a href="#rid3">3</a>]. If symptoms, pulmonary function, and HRCT show improvement over the course of approximately three months, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> is tapered gradually to 15 mg/day, as tolerated. </p><p></p><p class="bulletIndent1">If symptoms do not improve substantially, a second immunosuppressive agent can be added. Similarly, if symptoms and/or lung function recur during or after tapering <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, the dose can be returned to the level previously associated with disease control. Addition of a second immunosuppressive agent may enable tolerance of a lower dose of prednisone. (See <a class="local">'Additional immunosuppressive agents'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients without inflammatory features</strong> – Patients without inflammatory features (eg, no ground-glass opacities on HRCT, absence of BAL lymphocytosis, absence of histopathologic cellular interstitial pneumonia or granulomatous inflammation) are less likely to improve with glucocorticoids, so a reasonable alternative is not to give glucocorticoids, particularly if symptoms and lung function impairment are mild. For those who pursue a trial of glucocorticoids, we use a similar initial dose, but rapidly taper and discontinue after a three month trial in the absence of clear benefit [<a href="#rid3">3</a>]. Cytotoxic agents are unlikely to be of benefit in patients who do not respond to glucocorticoids. Other options include clinical trial participation and lung transplantation. (See <a class="local">'Lung transplantation'</a> below and <a class="local">'Antifibrotic agents'</a> below.)</p><p></p><p>Long-term glucocorticoid treatment is associated with a variety of adverse effects (eg, hyperglycemia, adrenal suppression, opportunistic infection, weight gain, cataracts, osteoporosis), so careful and ongoing assessment of risks and benefits is essential. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p class="headingAnchor" id="H25765960"><span class="h3">Additional immunosuppressive agents</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">Azathioprine</a> (AZA) and <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF) have been used in patients with chronic HP who have not responded to antigen removal and systemic glucocorticoid use, but these agents have not been examined in clinical trials of HP [<a href="#rid3">3,4,29-32</a>]. </p><p>Observational data suggest that these agents lead to improvements in lung function (DLCO) and appear to have fewer adverse events compared with glucocorticoid therapy alone [<a href="#rid29">29,30</a>]. In a retrospective study, 51 patients with chronic HP were treated with MMF and 19 with AZA; after 11 months, no improvement was noted with either agent in FEV<sub>1</sub>, but DLCO increased by 4 percent in both groups [<a href="#rid29">29</a>]. Six months after initiation of AZA or MMF, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> decreased by almost 4 mg/day from a prior mean dose of 12 mg/day. In another retrospective study, 30 patients with chronic HP treated with MMF or AZA therapy showed improvement in DLCO and reduction in glucocorticoid dose [<a href="#rid33">33</a>]. Retrospective analysis of 62 patients on AZA treatment for up to two years shows an improvement in lung function [<a href="#rid34">34</a>].</p><p>In a separate observational study that included 282 patients with fibrotic HP stratified by leukocyte telomere length, the use of AZA or MMF was not linked to improved survival in patients with normal telomere length (≥10<sup>th</sup> percentile for age). Specifically, the two-year transplant-free survival was 86 percent in those treated with AZA or MMF compared with 88 percent in untreated patients (adjusted HR 0.8, 95% CI 0.3-2.0) [<a href="#rid35">35</a>]. Conversely, in patients with short telomeres (&lt;10<sup>th</sup> percentile for age) treatment with AZA or MMF was strongly associated with worse transplant-free survival (48 versus 83 percent in untreated patients, adjusted HR 0.15 95% CI 0.06-0.42). The significant interaction between telomere length and poor outcome with immunosuppressants suggests that measuring telomere length in patients with chronic HP may help identify a population who might benefit more from alternative management strategies.</p><p>In a multicenter, retrospective, noninterventional study involving 344 patients with chronic HP, the effects AZA or MMF treatment were evaluated across various types of antigen exposures: avian (27 percent), mold (26 percent), other (4 percent), and unknown (43 percent). The study found no significant differences in patient characteristics, lung function, or disease progression among the different antigen groups. However, a notable finding was the observed worsening survival in patients with unknown antigen exposure who were treated with immunosuppression (HR 2.7; 95% CI, 1.01-6.9). This suggests a variable response to immunosuppressive therapy in chronic HP based on the type of antigen involved [<a href="#rid36">36</a>].</p><p>Prospective clinical trials are needed to clarify the role of AZA and MMF in the long-term management of chronic HP.</p><p>Information about the administration of AZA and MMF and potential adverse effects are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7994.html" rel="external">"Pharmacology and side effects of azathioprine when used in rheumatic diseases"</a> and  <a class="medical medical_review" href="/z/d/html/7990.html" rel="external">"Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases"</a>.)</p><p class="headingAnchor" id="H2574842105"><span class="h3">Antifibrotic agents</span><span class="headingEndMark"> — </span>For patients with chronic hypersensitivity pneumonitis and progressive fibrosis, treatment with the antifibrotic <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">nintedanib</a> may improve disease progression. The alternative antifibrotic agent <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">pirfenidone</a> has been less well-studied in this setting but is sometimes offered off-label if nintedanib cannot be used. When initiated, antifibrotic therapy is often added to immunosuppressive therapies, if tolerated. Dosing, administration, and monitoring of antifibrotic therapies are covered elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">"Treatment of idiopathic pulmonary fibrosis", section on 'Medical therapies'</a>.)</p><p>Antifibrotic therapies, such as <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">pirfenidone</a> and <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">nintedanib</a>, have been found to slow disease progression in idiopathic pulmonary fibrosis (see  <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">"Treatment of idiopathic pulmonary fibrosis", section on 'Nintedanib'</a> and  <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">"Treatment of idiopathic pulmonary fibrosis", section on 'Pirfenidone'</a>). This finding has led to considerable interest in the role for these therapies in other fibrosing interstitial lung diseases, including chronic fibrotic hypersensitivity pneumonitis. Although nintedanib shows a potential benefit in terms of lung function decline, whether antifibrotic therapies improve patient-important outcomes in those with chronic fibrotic hypersensitivity pneumonitis is less certain.</p><p>One trial compared <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">nintedanib</a> (150 mg twice daily) with placebo in 663 patients with fibrotic interstitial lung diseases (other than IPF) that affected at least 10 percent of the lung on high-resolution computed tomography (HRCT); 26 percent of participants had chronic hypersensitivity pneumonitis [<a href="#rid37">37</a>]. Requirements for trial entry included a relative decline in the FVC of at least 10 percent of the predicted value; a relative decline in the FVC of 5 to &lt;10 percent of predicted and worsening of respiratory symptoms or an increased extent of fibrosis on HRCT; or worsening of respiratory symptoms and an increased extent of fibrosis. After 52 weeks, the adjusted rate of decline in forced vital capacity was -80.8 mL/year in the nintedanib group and -187.8 mL/year in the placebo group with a between-group difference of 107.0 mL/year (95% CI 65.4 to 148.5). Between group differences in other end-points such as composite measures of activity and symptoms, and also frequency of acute exacerbations or death did not meet significance. The most common adverse event was diarrhea, reported in 67 and 24 percent of patients treated with nintedanib and placebo, respectively.</p><p><a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">Pirfenidone</a> has been assessed in two placebo-controlled trials that were terminated early due to slow recruitment. In the first trial, 127 patients with a variety of fibrotic interstitial lung diseases (45 percent of whom had chronic hypersensitivity pneumonitis) received pirfenidone or placebo for 48 weeks [<a href="#rid38">38</a>]. There was no clinically meaningful reduction in the rate of FVC decline or in progression-free survival. The other trial, which assessed pirfenidone (versus placebo) in 40 patients with fibrotic hypersensitivity pneumonitis, was underpowered to detect improvement or delayed decline in lung function [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H1551008363"><span class="h3">Lung transplantation</span><span class="headingEndMark"> — </span>For the patient who develops advanced lung disease due to HP, lung transplantation may be an option [<a href="#rid3">3,40</a>]. The indications for lung transplantation in HP are similar to those for other interstitial lung diseases and are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">"Treatment of idiopathic pulmonary fibrosis", section on 'Indications and choice of procedure'</a> and  <a class="medical medical_review" href="/z/d/html/4658.html" rel="external">"Lung transplantation: General guidelines for recipient selection"</a>.)</p><p>In general, patients with HP have excellent medium-term survival following lung transplantation. In a case series, 31 patients with HP underwent lung transplantation and were compared with 91 patients with idiopathic pulmonary fibrosis (IPF) transplanted at the same center [<a href="#rid40">40</a>]. The inciting allergen was identified in 12 patients; eight were exposed to birds, three to mold, and one to wood bark. Among patients with HP, survival at one, three, and five years post transplantation was 96, 89, and 89 percent, respectively, which compared with 86, 67, and 49 percent for patients with IPF. Two patients experienced recurrence of HP in the allograft: one had heavy occupational exposure to trees, possibly sequoias, and lived in a wooded area; the other had heavy exposure to birds and molds with positive serology to avian and fungal precipitins, and post-transplant HP followed a repeat exposure to pigeons. </p><p class="headingAnchor" id="H3030894966"><span class="h2">Future directions</span></p><p class="headingAnchor" id="H3349510883"><span class="h3">Rituximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a>, a B cell depleting monoclonal antibody, has been used in individual cases of refractory hypersensitivity pneumonitis [<a href="#rid41">41,42</a>]. Given that chronic progressive HP has a mixed immunopathogenesis that involves T cells and fibrosis in addition to antibody-mediated disease, B cell-depleting therapy may not be broadly beneficial. Among six patients with HP and severe respiratory impairment that was refractory to oral glucocorticoid and at least one other immunosuppressive agent, treatment with rituximab was associated with stabilization or improvement in three and progression in three [<a href="#rid42">42</a>]. A retrospective study in 20 patients with chronic HP showed that rituximab treatment of six months' duration may lead to stabilization or improvement of lung function in some patients [<a href="#rid43">43</a>]. </p><p class="headingAnchor" id="H554207392"><span class="h3">Leflunomide</span><span class="headingEndMark"> — </span>A retrospective study of <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a> treatment in 40 patients with chronic HP showed improvement in pulmonary function (FVC) at 12 months [<a href="#rid32">32</a>]. Non-fibrotic chronic HP patients had the largest gain in pulmonary function; patients with fibrotic chronic HP did not improve. Leflunomide treatment was associated with significant adverse effects leading to discontinuation of therapy in 40 percent of patients [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H3199492110"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>A specific monitoring schedule has not been established for HP [<a href="#rid3">3</a>]. For patients with an acute presentation of HP that resolves promptly, a follow-up visit is desirable to determine the success of antigen mitigation and resolution of disease, especially if antigen avoidance has not been successful. Continued low levels of exposure may lead to subclinical progression of lung injury.</p><p>For patients with subacute or chronic HP treated with glucocorticoids or additional immunosuppressive agents, follow-up visits to assess symptoms, potential adverse effects, and lung function (spirometry, pulse oximetry, and diffusing capacity for carbon monoxide [DLCO]) are reasonable at one to two month intervals [<a href="#rid3">3</a>]. Once <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> is tapered to &lt;20 mg daily, the interval can often be lengthened to three to six months, depending on the severity and trajectory of symptoms and potential for medication adverse effects. Repeat high-resolution computed tomography (HRCT) is based on symptoms and lung function but is often obtained three to six months after initiation of treatment.</p><p class="headingAnchor" id="H10"><span class="h1">PROGNOSIS</span></p><p class="headingAnchor" id="H2799863009"><span class="h2">Predictive features</span><span class="headingEndMark"> — </span>The long-term outcome of HP varies and depends on factors such as the specific causal antigen, duration of antigen exposure, and host response. Patients with acute HP who have complete avoidance of the causal antigen tend to experience near total recovery of lung function, although full recovery may take several years after the inciting exposure ceases [<a href="#rid4">4,44</a>]. Bird fancier's HP appears to have a worse prognosis than farmer's lung. The prognoses of other varieties of HP are less well described. In general, patients with evidence of pulmonary fibrosis on surgical lung biopsy have a poorer prognosis than those without such changes [<a href="#rid45">45-48</a>]. In fact, in one large cohort of patients with fibrotic lung disease, approximately 60 percent of both those with chronic fibrotic HP and those with idiopathic pulmonary fibrosis demonstrated disease progression (defined by forced vital capacity [FVC] decline of more than 10 percent, a 5 to 10 percent FVC decline with worsening respiratory symptoms or an increase in radiographic fibrosis, both worsening symptoms and radiographic fibrosis, lung transplant, or death) over two years [<a href="#rid49">49</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>ILD-GAP model</strong> – Decline in lung function over time is a poor prognostic sign, particularly for patients with chronic HP [<a href="#rid50">50</a>]. Similar to the GAP model used for predicting mortality in patients with IPF [<a href="#rid51">51</a>], the interstitial lung disease (ILD)-GAP model, which combines age, gender, and measures of pulmonary function (FVC and diffusing capacity for carbon monoxide [DLCO]) with a variable to account for the ILD subtype, can help to predict mortality in chronic HP [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/z/d/html/113935.html" rel="external">"Prognosis and monitoring of idiopathic pulmonary fibrosis", section on 'Predictors of mortality'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging</strong> – While chest radiographs at the time of diagnosis do not correlate with outcome, high-resolution computed tomography (HRCT) patterns may be useful in predicting prognosis in chronic HP [<a href="#rid47">47,53-59</a>]. In particular, a greater severity of traction bronchiectasis and increased extent of honeycombing are associated with increasing mortality [<a href="#rid54">54,60</a>]. Similarly, among 117 patients with biopsy-proven HP, HRCT-based characterization correlated with nonfibrotic HP (no traction bronchiectasis, or honeycombing), had a longer event-free survival (14.73 years) than nonhoneycomb fibrosis (7.95 years) or honeycomb fibrosis (2.76 years) [<a href="#rid59">59</a>]. By comparison, event-free survival was 2.81 years among 161 patients with idiopathic pulmonary fibrosis (IPF).</p><p></p><p class="bulletIndent1">A model derived from fully automated extraction of HRCT features performs comparably to models based upon patient demographics and pulmonary function testing results [<a href="#rid61">61</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology</strong> – Certain histopathologic patterns appear predictive of mortality and shorter transplant-free survival [<a href="#rid45">45-48</a>]. In a longitudinal cohort of 119 patients with chronic HP, surgical lung biopsies were reviewed prospectively [<a href="#rid48">48</a>]. Histopathologic patterns of fibrotic nonspecific interstitial pneumonitis (NSIP), bronchiolocentric fibrosis, and usual interstitial pneumonitis (UIP) were associated with a poor prognosis compared with the patterns of cellular NSIP and peribronchiolar inflammation with poorly-formed granulomas (PI-PFG). The presence of fibroblast foci or dense collagen fibrosis were independent predictors of death or lung transplant. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary hypertension</strong> – Among patients with chronic HP, development of symptomatic pulmonary hypertension correlates with the severity of interstitial lung disease and portends a worse survival [<a href="#rid62">62,63</a>]. In most patients, pulmonary hypertension is attributable to the interstitial lung disease, but a small portion have type 2 pulmonary hypertension related to left heart dysfunction.</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Farmer's lung</span><span class="headingEndMark"> — </span>Many investigators have studied the clinical course of farmer's lung and have reached a similar conclusion: most farmers recover from their original illness with only minor, if any, functional abnormalities, and very few progress to an advanced, debilitated state [<a href="#rid10">10,11,24,64,65</a>]. Approximately 50 percent of farmers develop chronic lung impairment, but the alterations are usually minor [<a href="#rid64">64</a>]. Most have obstructive abnormalities, often associated with emphysematous changes on high-resolution computed tomography (HRCT) [<a href="#rid66">66,67</a>]. As an example, one 14 year study of 89 patients with farmer's lung and 84 controls matched for age, sex, and smoking habits found a higher incidence of airflow obstruction in those with farmer's lung (33 versus 17 percent) [<a href="#rid66">66</a>].</p><p>In general, PaO<sub>2</sub> improves more rapidly than the forced vital capacity (FVC), while recovery of the diffusing capacity of carbon monoxide (DLCO) takes longest [<a href="#rid65">65</a>]. The pulmonary function of farmer's lung patients continues to improve for up to two years after the initial acute episode, and this improvement may be seen even if exposure continues.</p><p>Attempts to identify factors that influence prognosis have yielded conflicting results [<a href="#rid16">16,24,68-71</a>]. However, repeated mild attacks appear more likely to result in disability than a single, acute attack [<a href="#rid67">67,72</a>]. This may reflect better adherence to antigen avoidance measures in the latter group, as well as resolution of granulomatous inflammation before significant pulmonary fibrosis has occurred.</p><p class="headingAnchor" id="H12"><span class="h2">Bird fancier's lung</span><span class="headingEndMark"> — </span>Bird fancier's lung (also called pigeon breeder's disease) has not been as well studied as farmer's lung, but its prognosis appears worse. We and others have noted that many of our chronic, progressive, and fatal cases of HP had disease secondary to bird antigen exposure [<a href="#rid40">40,55,73-77</a>]. Nevertheless, some patients do relatively well despite continued antigen exposure after an acute episode of HP [<a href="#rid13">13</a>]. In one report of 18 such patients who were followed for 10 years, only five had troublesome symptoms and four had some residual abnormalities in pulmonary function.</p><p>The poorer outcome in some patients with this disorder may be due to a higher degree of exposure to HP antigens than in farmer's lung and to the persistence of avian antigens in the home environment despite attempts at decontamination [<a href="#rid7">7</a>]. Continued domestic exposure may account for the substantial mortality (29 percent at five years) seen in Mexican patients with chronic pigeon breeder's lung [<a href="#rid75">75</a>].</p><p>Several factors affect prognosis with bird fancier's lung [<a href="#rid8">8,46,78-81</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The duration of exposure appears important. One study of nine patients found complete recovery among persons exposed to bird antigens for less than six months but documented residual abnormalities in those with longer exposures [<a href="#rid78">78</a>]. Similar findings were reported in a series of 24 patients with bird fancier's lung in which patients exposed for less than two years had a more favorable outcome than those exposed for a longer period [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A wide range of histopathologic changes has been reported among patients with bird fancier's lung, and these findings may help predict the subsequent clinical course of disease [<a href="#rid46">46</a>]. In addition to hypersensitivity pneumonitis, changes associated with several forms of idiopathic interstitial pneumonia have been identified. As an example, patients with organizing pneumonia or cellular NSIP appear to have a better prognosis than those with evidence of fibrosing pneumonitis (either fibrotic NSIP or a UIP-like pattern with a distinct centrilobular fibrosis) on biopsy [<a href="#rid46">46,82</a>]. (See  <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">"Idiopathic interstitial pneumonias: Classification and pathology"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presentation (acute, subacute, or chronic) may correlate with recovery or progression. In a study of 18 patients followed for a median of 11 years, an acute presentation was associated with a better prognosis [<a href="#rid8">8</a>]. This association has been noted in some [<a href="#rid83">83</a>], but not all [<a href="#rid78">78</a>] subsequent studies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of digital clubbing predicts a worse outcome [<a href="#rid81">81</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Older patients tend to have a less complete recovery than younger patients [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Greater exposure intensity results in accelerated declines in lung function [<a href="#rid80">80</a>].</p><p></p><p class="headingAnchor" id="H2095354323"><span class="h1">MITIGATION AND PREVENTION</span><span class="headingEndMark"> — </span>The incidence of HP can be reduced by diminishing exposure to provocative antigens by interventions such as minimizing contact with potential inciting agents, reducing microbial contamination of the work or home environment, and using protective equipment. For patients with HP, these interventions can help mitigate further exposure.</p><p class="headingAnchor" id="H865492140"><span class="h2">Reduction of antigenic burden</span><span class="headingEndMark"> — </span>Alteration in the handling and storage of potential sources of microbial antigens can diminish the occurrence of HP [<a href="#rid5">5,84-87</a>]. As examples, enclosing machines and improving ventilation reduces exposure to metal working fluids [<a href="#rid86">86,87</a>]; use of antimicrobial solutions in sugar cane processing diminishes fungal growth and the development of bagassosis [<a href="#rid88">88</a>], and reducing outdoor storage of sawn wood and using a new kiln to dry wood decreases mold exposure and respiratory symptoms in sawmills [<a href="#rid84">84</a>].</p><p class="headingAnchor" id="H2406180103"><span class="h2">Design and maintenance of facilities</span><span class="headingEndMark"> — </span>Indoor microbial contamination is usually related to problems with moisture control [<a href="#rid89">89</a>]. Appropriate design of facilities may reduce stagnant water that is prone to microbial overgrowth. Thus, humidity in occupied buildings should be maintained below 60 percent, carpeting should be avoided in areas where persistent moisture is likely to be present, and water in heating, ventilating, and air conditioning systems should not be recirculated.</p><p>Preventive maintenance should be performed routinely in order to ensure that all heating, ventilation, and air conditioning equipment is properly maintained and that the indoor environment is clean. Portable humidifiers or vaporizers should be drained daily with removal of all slime and sterilized frequently with either chlorine bleach or hydrogen peroxide [<a href="#rid89">89</a>].</p><p>Water damage should be immediately repaired because microbial colonization occurs quickly and can be very difficult to eradicate. Water-damaged furnishings, drywall, and carpeting should be removed.</p><p class="headingAnchor" id="H3301626181"><span class="h2">Protective devices</span><span class="headingEndMark"> — </span>Devices to limit inhalation of inciting antigens may be useful when complete elimination of these antigens is impossible, although supportive data are limited [<a href="#rid5">5,10,11,86</a>]. As an example, the level of antigen exposure can sometimes be controlled by the appropriate use of environmental controls such as a specialized filter in the return ducts of a central air conditioning system [<a href="#rid90">90</a>].</p><p>The efficacy of various types of personal respirators in preventing antigen sensitization and disease progression has not been established. Their use is most appropriate when avoidance of the causative antigen cannot easily and rapidly be achieved [<a href="#rid5">5,91,92</a>]. Helmet-type powered air purifying respirators have been used to prevent episodic exposure in individuals with previous acute episodes of farmer's lung, but are cumbersome to wear for prolonged periods. Data on the use of dust respirators are conflicting and further research is needed to evaluate whether they are sufficiently protective [<a href="#rid5">5,91-93</a>].</p><p class="headingAnchor" id="H926310063"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118793.html" rel="external">"Society guideline links: Interstitial lung disease"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with hypersensitivity pneumonitis (HP) should be encouraged to completely avoid (preferred) ongoing exposure to the provocative antigen(s), particularly patients with progressive disease. As an exception, some patients, such as those with farmers’ lung who have prompt resolution of initial symptoms, may do well despite continued low-level exposure. (See <a class="local">'Antigen avoidance'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with acute HP, mild or intermittent symptoms, and minimal to no abnormalities on pulmonary function tests (PFTs), avoidance of the culprit antigen will usually lead to resolution of symptoms and lung function abnormalities. (See <a class="local">'Antigen avoidance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with symptomatic acute or subacute HP, reduced lung function, and diffuse lung disease on high-resolution computed tomography (HRCT), but no evidence of infection, in addition to antigen avoidance, we suggest a course of oral glucocorticoids, based on limited evidence that therapy will shorten the duration of symptoms (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The usual initial dose is the equivalent of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 0.5 mg/kg per day (up to 30 mg/day); the initial dose is maintained for one to two weeks.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Once the patient is symptomatically improved, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> is tapered over the next two to four weeks. Maintenance therapy is rarely required, usually only when a patient is unable to avoid the culprit antigen. (See <a class="local">'Glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Supportive care, such as smoking cessation, seasonal influenza and pneumococcal vaccinations, pulmonary rehabilitation, and supplemental oxygen) should be provided to patients with chronic HP, as needed. (See <a class="local">'Supportive care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with chronic or fibrotic HP, we suggest a trial of oral glucocorticoids (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The usual initial dose of glucocorticoid is the equivalent of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 0.5 mg/kg per day (up to 30 mg per day) for four to eight weeks followed by tapering to 10 to 20 mg per day by three months, with subsequent tapering as guided by symptoms and lung function. A reasonable alternative is not to give glucocorticoids, particularly if symptoms and lung function impairment are mild and inflammatory features are absent. For patients without inflammatory features who undergo a trial of glucocorticoid therapy, we reassess after three months and taper off of prednisone rapidly if there is no clear evidence of benefit. (See <a class="local">'Glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with chronic fibrotic hypersensitivity pneumonitis and progressive fibrosis, we suggest treatment with the antifibrotic <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">nintedanib</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), which may reduce subsequent lung function decline. For patients with progressive pulmonary fibrosis who cannot use nintedanib, off-label treatment with <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">pirfenidone</a> is a reasonable alternative. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">Azathioprine</a> (AZA) and <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF) have been used with some success in patients with chronic HP who have not responded to antigen removal and systemic glucocorticoid therapy, but clinical trial data are lacking. (See <a class="local">'Additional immunosuppressive agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lung transplantation is an option for selected patients with advanced chronic HP, and has been shown to have excellent medium-term survival. Recurrent exposure may lead to HP in the allograft. (See <a class="local">'Lung transplantation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The majority of patients with acute or subacute HP experience near total recovery of lung function, which in some cases may take several years after the inciting exposure ceases. However, more fibrotic histopathologic patterns have a poorer prognosis than more inflammatory patterns. Fibroblast foci and dense collagen fibrosis may be independent predictors of mortality or need for lung transplantation. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bird fancier's lung appears to have a worse prognosis than farmer's lung; this may be due to a higher concentration and persistence of avian antigens in the home environment compared with exposure to antigens that cause farmer's lung. (See <a class="local">'Bird fancier's lung'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The incidence of HP can be reduced by diminishing exposure to the agricultural dusts, bioaerosols, and chemicals that are known or found to be causative. Methods to reduce exposure include reducing microbial contamination and excess humidity in the work or home environment, maintaining ventilation systems properly, and/or using protective equipment. (See <a class="local">'Mitigation and prevention'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Selman M, Pardo A, King TE Jr. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med 2012; 186:314.</a></li><li><a class="nounderline abstract_t">Girard M, Israël-Assayag E, Cormier Y. Pathogenesis of hypersensitivity pneumonitis. Curr Opin Allergy Clin Immunol 2004; 4:93.</a></li><li><a class="nounderline abstract_t">Salisbury ML, Myers JL, Belloli EA, et al. Diagnosis and Treatment of Fibrotic Hypersensitivity Pneumonia. Where We Stand and Where We Need to Go. Am J Respir Crit Care Med 2017; 196:690.</a></li><li><a class="nounderline abstract_t">Vasakova M, Morell F, Walsh S, et al. Hypersensitivity Pneumonitis: Perspectives in Diagnosis and Management. Am J Respir Crit Care Med 2017; 196:680.</a></li><li><a class="nounderline abstract_t">Quirce S, Vandenplas O, Campo P, et al. Occupational hypersensitivity pneumonitis: an EAACI position paper. Allergy 2016; 71:765.</a></li><li><a class="nounderline abstract_t">Hanak V, Kalra S, Aksamit TR, et al. Hot tub lung: presenting features and clinical course of 21 patients. Respir Med 2006; 100:610.</a></li><li><a class="nounderline abstract_t">Tsutsui T, Miyazaki Y, Kuramochi J, et al. The amount of avian antigen in household dust predicts the prognosis of chronic bird-related hypersensitivity pneumonitis. Ann Am Thorac Soc 2015; 12:1013.</a></li><li><a class="nounderline abstract_t">Zacharisen MC, Schlueter DP, Kurup VP, Fink JN. The long-term outcome in acute, subacute, and chronic forms of pigeon breeder's disease hypersensitivity pneumonitis. Ann Allergy Asthma Immunol 2002; 88:175.</a></li><li><a class="nounderline abstract_t">Tsushima K, Furuya S, Yoshikawa S, et al. Therapeutic effects for hypersensitivity pneumonitis induced by Japanese mushroom (Bunashimeji). Am J Ind Med 2006; 49:826.</a></li><li><a class="nounderline abstract_t">Cormier Y, Bélanger J. Long-term physiologic outcome after acute farmer's lung. Chest 1985; 87:796.</a></li><li><a class="nounderline abstract_t">Braun SR, doPico GA, Tsiatis A, et al. Farmer's lung disease: long-term clinical and physiologic outcome. Am Rev Respir Dis 1979; 119:185.</a></li><li><a class="nounderline abstract_t">Cuthbert OD, Gordon MF. Ten year follow up of farmers with farmer's lung. Br J Ind Med 1983; 40:173.</a></li><li><a class="nounderline abstract_t">Bourke SJ, Banham SW, Carter R, et al. Longitudinal course of extrinsic allergic alveolitis in pigeon breeders. Thorax 1989; 44:415.</a></li><li><a class="nounderline abstract_t">Barnes H, Chambers D, Grainge C, et al. Clinical utility of a standardized chronic hypersensitivity pneumonitis exposure questionnaire. Respirology 2023; 28:366.</a></li><li><a class="nounderline abstract_t">Jacobs RL, Thorner RE, Holcomb JR, et al. Hypersensitivity pneumonitis caused by Cladosporium in an enclosed hot-tub area. Ann Intern Med 1986; 105:204.</a></li><li><a class="nounderline abstract_t">Barbee RA, Callies Q, Dickie HA, Rankin J. The long-term prognosis in farmer's lung. Am Rev Respir Dis 1968; 97:223.</a></li><li><a class="nounderline abstract_t">Craig TJ, Hershey J, Engler RJ, et al. Bird antigen persistence in the home environment after removal of the bird. Ann Allergy 1992; 69:510.</a></li><li><a class="nounderline abstract_t">Mönkäre S. Influence of corticosteroid treatment on the course of farmer's lung. Eur J Respir Dis 1983; 64:283.</a></li><li><a class="nounderline abstract_t">Kokkarinen JI, Tukiainen HO, Terho EO. Effect of corticosteroid treatment on the recovery of pulmonary function in farmer's lung. Am Rev Respir Dis 1992; 145:3.</a></li><li><a class="nounderline abstract_t">Ejima M, Okamoto T, Suzuki T, et al. Efficacy of treatment with corticosteroids for fibrotic hypersensitivity pneumonitis: a propensity score-matched cohort analysis. BMC Pulm Med 2021; 21:243.</a></li><li><a class="nounderline abstract_t">Xu JF, Shen L, Zhang Y, et al. Lung biopsy-proved hypersensitivity pneumonitis without known offending antigen: characteristics and follow-up. Clin Respir J 2014; 8:297.</a></li><li><a class="nounderline abstract_t">Ohshimo S, Bonella F, Guzman J, Costabel U. Hypersensitivity pneumonitis. Immunol Allergy Clin North Am 2012; 32:537.</a></li><li><a class="nounderline abstract_t">Carlsen KH, Leegaard J, Lund OD, Skjaervik H. Allergic alveolitis in a 12-year-old boy: treatment with budesonide nebulizing solution. Pediatr Pulmonol 1992; 12:257.</a></li><li><a class="nounderline abstract_t">Mönkäre S, Haahtela T. Farmer's lung--a 5-year follow-up of eighty-six patients. Clin Allergy 1987; 17:143.</a></li><li><a class="nounderline abstract_t">Fernández Pérez ER, Swigris JJ, Forssén AV, et al. Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest 2013; 144:1644.</a></li><li><a class="nounderline abstract_t">Sema M, Miyazaki Y, Tsutsui T, et al. Environmental levels of avian antigen are relevant to the progression of chronic hypersensitivity pneumonitis during antigen avoidance. Immun Inflamm Dis 2018; 6:154.</a></li><li><a class="nounderline abstract_t">Petnak T, Thongprayoon C, Baqir M, et al. Antigen identification and avoidance on outcomes in fibrotic hypersensitivity pneumonitis. Eur Respir J 2022; 60.</a></li><li><a class="nounderline abstract_t">Spagnolo P, Rossi G, Cavazza A, et al. Hypersensitivity Pneumonitis: A Comprehensive Review. J Investig Allergol Clin Immunol 2015; 25:237.</a></li><li><a class="nounderline abstract_t">Morisset J, Johannson KA, Vittinghoff E, et al. Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis. Chest 2017; 151:619.</a></li><li><a class="nounderline abstract_t">Adegunsoye A, Oldham JM, Fernández Pérez ER, et al. Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis. ERJ Open Res 2017; 3.</a></li><li><a class="nounderline abstract_t">Raimundo S, Pimenta AC, Cruz-Martins N, et al. Insights on chronic hypersensitivity pneumonitis' treatment: Factors associated with a favourable response to azathioprine. Life Sci 2021; 272:119274.</a></li><li><a class="nounderline abstract_t">Noh S, Yadav R, Li M, et al. Use of leflunomide in patients with chronic hypersensitivity pneumonitis. BMC Pulm Med 2020; 20:199.</a></li><li><a class="nounderline abstract_t">Fiddler CA, Simler N, Thillai M, Parfrey H. Use of mycophenolate mofetil and azathioprine for the treatment of chronic hypersensitivity pneumonitis-A single-centre experience. Clin Respir J 2019; 13:791.</a></li><li><a class="nounderline abstract_t">Terras Alexandre A, Martins N, Raimundo S, et al. Impact of Azathioprine use in chronic hypersensitivity pneumonitis patients. Pulm Pharmacol Ther 2020; 60:101878.</a></li><li><a class="nounderline abstract_t">Zhang D, Adegunsoye A, Oldham JM, et al. Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease. Eur Respir J 2023; 62.</a></li><li><a class="nounderline abstract_t">Mullin ML, Fernandez G, Marinescu DC, et al. Impact of Antigen Exposure on Outcomes and Treatment Response in Fibrotic Hypersensitivity Pneumonitis. Chest 2023.</a></li><li><a class="nounderline abstract_t">Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 2019; 381:1718.</a></li><li><a class="nounderline abstract_t">Behr J, Prasse A, Kreuter M, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med 2021; 9:476.</a></li><li><a class="nounderline abstract_t">Fernández Pérez ER, Crooks JL, Lynch DA, et al. Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety. Thorax 2023; 78:1097.</a></li><li><a class="nounderline abstract_t">Kern RM, Singer JP, Koth L, et al. Lung transplantation for hypersensitivity pneumonitis. Chest 2015; 147:1558.</a></li><li><a class="nounderline abstract_t">Lota HK, Keir GJ, Hansell DM, et al. Novel use of rituximab in hypersensitivity pneumonitis refractory to conventional treatment. Thorax 2013; 68:780.</a></li><li><a class="nounderline abstract_t">Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 2014; 19:353.</a></li><li><a class="nounderline abstract_t">Ferreira M, Borie R, Crestani B, et al. Efficacy and safety of rituximab in patients with chronic hypersensitivity pneumonitis (cHP): A retrospective, multicentric, observational study. Respir Med 2020; 172:106146.</a></li><li><a class="nounderline abstract_t">Nogueira R, Melo N, Novais E Bastos H, et al. Hypersensitivity pneumonitis: Antigen diversity and disease implications. Pulmonology 2019; 25:97.</a></li><li><a class="nounderline abstract_t">Vourlekis JS, Schwarz MI, Cherniack RM, et al. The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis. Am J Med 2004; 116:662.</a></li><li><a class="nounderline abstract_t">Ohtani Y, Saiki S, Kitaichi M, et al. Chronic bird fancier's lung: histopathological and clinical correlation. An application of the 2002 ATS/ERS consensus classification of the idiopathic interstitial pneumonias. Thorax 2005; 60:665.</a></li><li><a class="nounderline abstract_t">Sahin H, Brown KK, Curran-Everett D, et al. Chronic hypersensitivity pneumonitis: CT features comparison with pathologic evidence of fibrosis and survival. Radiology 2007; 244:591.</a></li><li><a class="nounderline abstract_t">Wang P, Jones KD, Urisman A, et al. Pathologic Findings and Prognosis in a Large Prospective Cohort of Chronic Hypersensitivity Pneumonitis. Chest 2017; 152:502.</a></li><li><a class="nounderline abstract_t">Hambly N, Farooqi MM, Dvorkin-Gheva A, et al. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. Eur Respir J 2022; 60.</a></li><li><a class="nounderline abstract_t">Gimenez A, Storrer K, Kuranishi L, et al. Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis. Thorax 2018; 73:391.</a></li><li><a class="nounderline abstract_t">Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156:684.</a></li><li><a class="nounderline abstract_t">Ryerson CJ, Vittinghoff E, Ley B, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest 2014; 145:723.</a></li><li><a class="nounderline abstract_t">Tateishi T, Ohtani Y, Takemura T, et al. Serial high-resolution computed tomography findings of acute and chronic hypersensitivity pneumonitis induced by avian antigen. J Comput Assist Tomogr 2011; 35:272.</a></li><li><a class="nounderline abstract_t">Walsh SL, Sverzellati N, Devaraj A, et al. Chronic hypersensitivity pneumonitis: high resolution computed tomography patterns and pulmonary function indices as prognostic determinants. Eur Radiol 2012; 22:1672.</a></li><li><a class="nounderline abstract_t">Mooney JJ, Elicker BM, Urbania TH, et al. Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis. Chest 2013; 144:586.</a></li><li><a class="nounderline abstract_t">Chung JH, Zhan X, Cao M, et al. Presence of Air Trapping and Mosaic Attenuation on Chest Computed Tomography Predicts Survival in Chronic Hypersensitivity Pneumonitis. Ann Am Thorac Soc 2017; 14:1533.</a></li><li><a class="nounderline abstract_t">Hanak V, Golbin JM, Hartman TE, Ryu JH. High-resolution CT findings of parenchymal fibrosis correlate with prognosis in hypersensitivity pneumonitis. Chest 2008; 134:133.</a></li><li><a class="nounderline abstract_t">Chung JH, Montner SM, Adegunsoye A, et al. CT findings associated with survival in chronic hypersensitivity pneumonitis. Eur Radiol 2017; 27:5127.</a></li><li><a class="nounderline abstract_t">Salisbury ML, Gu T, Murray S, et al. Hypersensitivity Pneumonitis: Radiologic Phenotypes Are Associated With Distinct Survival Time and Pulmonary Function Trajectory. Chest 2019; 155:699.</a></li><li><a class="nounderline abstract_t">Chiba S, Tsuchiya K, Akashi T, et al. Chronic Hypersensitivity Pneumonitis With a Usual Interstitial Pneumonia-Like Pattern: Correlation Between Histopathologic and Clinical Findings. Chest 2016; 149:1473.</a></li><li><a class="nounderline abstract_t">Jacob J, Bartholmai BJ, Rajagopalan S, et al. Automated computer-based CT stratification as a predictor of outcome in hypersensitivity pneumonitis. Eur Radiol 2017; 27:3635.</a></li><li><a class="nounderline abstract_t">Koschel DS, Cardoso C, Wiedemann B, et al. Pulmonary hypertension in chronic hypersensitivity pneumonitis. Lung 2012; 190:295.</a></li><li><a class="nounderline abstract_t">Oliveira RK, Pereira CA, Ramos RP, et al. A haemodynamic study of pulmonary hypertension in chronic hypersensitivity pneumonitis. Eur Respir J 2014; 44:415.</a></li><li><a class="nounderline abstract_t">Lalancette M, Carrier G, Laviolette M, et al. Farmer's lung. Long-term outcome and lack of predictive value of bronchoalveolar lavage fibrosing factors. Am Rev Respir Dis 1993; 148:216.</a></li><li><a class="nounderline abstract_t">Kokkarinen JI, Tukiainen HO, Terho EO. Recovery of pulmonary function in farmer's lung. A five-year follow-up study. Am Rev Respir Dis 1993; 147:793.</a></li><li><a class="nounderline abstract_t">Erkinjuntti-Pekkanen R, Kokkarinen JI, Tukiainen HO, et al. Long-term outcome of pulmonary function in farmer's lung: a 14 year follow-up with matched controls. Eur Respir J 1997; 10:2046.</a></li><li><a class="nounderline abstract_t">Erkinjuntti-Pekkanen R, Rytkonen H, Kokkarinen JI, et al. Long-term risk of emphysema in patients with farmer's lung and matched control farmers. Am J Respir Crit Care Med 1998; 158:662.</a></li><li><a class="nounderline abstract_t">Reynolds HY. Hypersensitivity pneumonitis: correlation of cellular and immunologic changes with clinical phases of disease. Lung 1988; 166:189.</a></li><li><a class="nounderline abstract_t">Phanuphak P, Salvaggio J, Fink J, Kohler P. Incidence of serum precipitins against organic-dust antigens in different populations by counterimmunoelectrophoresis. Chest 1975; 68:753.</a></li><li><a class="nounderline abstract_t">Hapke EJ, Seal RM, Thomas GO, et al. Farmer's lung. A clinical, radiographic, functional, and serological correlation of acute and chronic stages. Thorax 1968; 23:451.</a></li><li><a class="nounderline abstract_t">Laviolette M, Cormier Y, Loiseau A, et al. Bronchoalveolar mast cells in normal farmers and subjects with farmer's lung. Diagnostic, prognostic, and physiologic significance. Am Rev Respir Dis 1991; 144:855.</a></li><li><a class="nounderline abstract_t">Leblanc P, Bélanger J, Laviolette M, Cormier Y. Relationship among antigen contact, alveolitis, and clinical status in farmer's lung disease. Arch Intern Med 1986; 146:153.</a></li><li><a class="nounderline abstract_t">Grammer LC, Roberts M, Lerner C, Patterson R. Clinical and serologic follow-up of four children and five adults with bird-fancier's lung. J Allergy Clin Immunol 1990; 85:655.</a></li><li><a class="nounderline abstract_t">Remy-Jardin M, Remy J, Wallaert B, Müller NL. Subacute and chronic bird breeder hypersensitivity pneumonitis: sequential evaluation with CT and correlation with lung function tests and bronchoalveolar lavage. Radiology 1993; 189:111.</a></li><li><a class="nounderline abstract_t">Pérez-Padilla R, Salas J, Chapela R, et al. Mortality in Mexican patients with chronic pigeon breeder's lung compared with those with usual interstitial pneumonia. Am Rev Respir Dis 1993; 148:49.</a></li><li><a class="nounderline abstract_t">Buschman DL, Gamsu G, Waldron JA Jr, et al. Chronic hypersensitivity pneumonitis: use of CT in diagnosis. AJR Am J Roentgenol 1992; 159:957.</a></li><li><a class="nounderline abstract_t">Fink JN, Sosman AJ, Barboriak JJ, et al. Pigeon breeders' disease. A clinical study of a hypersensitivity pneumonitis. Ann Intern Med 1968; 68:1205.</a></li><li><a class="nounderline abstract_t">Allen DH, Williams GV, Woolcock AJ. Bird breeder's hypersensitivity pneumonitis: progress studies of lung function after cessation of exposure to the provoking antigen. Am Rev Respir Dis 1976; 114:555.</a></li><li><a class="nounderline abstract_t">de Gracia J, Morell F, Bofill JM, et al. Time of exposure as a prognostic factor in avian hypersensitivity pneumonitis. Respir Med 1989; 83:139.</a></li><li><a class="nounderline abstract_t">Schmidt CD, Jensen RL, Christensen LT, et al. Longitudinal pulmonary function changes in pigeon breeders. Chest 1988; 93:359.</a></li><li><a class="nounderline abstract_t">Sansores R, Salas J, Chapela R, et al. Clubbing in hypersensitivity pneumonitis. Its prevalence and possible prognostic role. Arch Intern Med 1990; 150:1849.</a></li><li><a class="nounderline abstract_t">Miyazaki Y, Tateishi T, Akashi T, et al. Clinical predictors and histologic appearance of acute exacerbations in chronic hypersensitivity pneumonitis. Chest 2008; 134:1265.</a></li><li><a class="nounderline abstract_t">Ohtani Y, Saiki S, Sumi Y, et al. Clinical features of recurrent and insidious chronic bird fancier's lung. Ann Allergy Asthma Immunol 2003; 90:604.</a></li><li><a class="nounderline abstract_t">Færden K, Lund MB, Mogens Aaløkken T, et al. Hypersensitivity pneumonitis in a cluster of sawmill workers: a 10-year follow-up of exposure, symptoms, and lung function. Int J Occup Environ Health 2014; 20:167.</a></li><li><a class="nounderline abstract_t">Bracker A, Storey E, Yang C, Hodgson MJ. An outbreak of hypersensitivity pneumonitis at a metalworking plant: a longitudinal assessment of intervention effectiveness. Appl Occup Environ Hyg 2003; 18:96.</a></li><li><a class="nounderline abstract_t">Burge PS. Hypersensitivity Pneumonitis Due to Metalworking Fluid Aerosols. Curr Allergy Asthma Rep 2016; 16:59.</a></li><li><a class="nounderline abstract_t">Zacharisen MC, Fink JN. Hypersensitivity pneumonitis and related conditions in the work environment. Immunol Allergy Clin North Am 2011; 31:769.</a></li><li><a class="nounderline abstract_t">Knight BW. Prevention of bagassosis by addition of propionic acid to sugar cane waste. Occup Health (Lond) 1970; 22:221.</a></li><li><a class="nounderline abstract_t">Rose CS. Water-related lung diseases. Occup Med 1992; 7:271.</a></li><li><a class="nounderline abstract_t">Jacobs RL, Andrews CP, Jacobs FO. Hypersensitivity pneumonitis treated with an electrostatic dust filter. Ann Intern Med 1989; 110:115.</a></li><li><a class="nounderline abstract_t">Hendrick DJ, Marshall R, Faux JA, Krall JM. Protective value of dust respirators in extrinsic allergic alveolitis: clinical assessment using inhalation provocation tests. Thorax 1981; 36:917.</a></li><li><a class="nounderline abstract_t">Müller-Wening D, Repp H. Investigation on the protective value of breathing masks in farmer's lung using an inhalation provocation test. Chest 1989; 95:100.</a></li><li><a class="nounderline abstract_t">Anderson K, Walker A, Boyd G. The long-term effect of a positive pressure respirator on the specific antibody response in pigeon breeders. Clin Exp Allergy 1989; 19:45.</a></li></ol></div><div id="topicVersionRevision">Topic 4311 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22679012" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15021060" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pathogenesis of hypersensitivity pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28002680" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Diagnosis and Treatment of Fibrotic Hypersensitivity Pneumonia. Where We Stand and Where We Need to Go.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28598197" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hypersensitivity Pneumonitis: Perspectives in Diagnosis and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26913451" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Occupational hypersensitivity pneumonitis: an EAACI position paper.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16194601" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hot tub lung: presenting features and clinical course of 21 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26010749" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The amount of avian antigen in household dust predicts the prognosis of chronic bird-related hypersensitivity pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11868922" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The long-term outcome in acute, subacute, and chronic forms of pigeon breeder's disease hypersensitivity pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16948148" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Therapeutic effects for hypersensitivity pneumonitis induced by Japanese mushroom (Bunashimeji).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3996070" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Long-term physiologic outcome after acute farmer's lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/434591" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Farmer's lung disease: long-term clinical and physiologic outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6830713" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Ten year follow up of farmers with farmer's lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2763241" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Longitudinal course of extrinsic allergic alveolitis in pigeon breeders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36336654" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical utility of a standardized chronic hypersensitivity pneumonitis exposure questionnaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3729202" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Hypersensitivity pneumonitis caused by Cladosporium in an enclosed hot-tub area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5637938" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The long-term prognosis in farmer's lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1471783" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Bird antigen persistence in the home environment after removal of the bird.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6861923" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Influence of corticosteroid treatment on the course of farmer's lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1731594" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Effect of corticosteroid treatment on the recovery of pulmonary function in farmer's lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34281549" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Efficacy of treatment with corticosteroids for fibrotic hypersensitivity pneumonitis: a propensity score-matched cohort analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24188571" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Lung biopsy-proved hypersensitivity pneumonitis without known offending antigen: characteristics and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23102065" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Hypersensitivity pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1614753" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Allergic alveolitis in a 12-year-old boy: treatment with budesonide nebulizing solution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3581462" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Farmer's lung--a 5-year follow-up of eighty-six patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23828161" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29168324" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Environmental levels of avian antigen are relevant to the progression of chronic hypersensitivity pneumonitis during antigen avoidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35236720" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Antigen identification and avoidance on outcomes in fibrotic hypersensitivity pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26310038" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hypersensitivity Pneumonitis: A Comprehensive Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27816444" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28845429" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33621590" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Insights on chronic hypersensitivity pneumonitis' treatment: Factors associated with a favourable response to azathioprine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32693781" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Use of leflunomide in patients with chronic hypersensitivity pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31464073" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Use of mycophenolate mofetil and azathioprine for the treatment of chronic hypersensitivity pneumonitis-A single-centre experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31862300" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Impact of Azathioprine use in chronic hypersensitivity pneumonitis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37591536" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38128609" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Impact of Antigen Exposure on Outcomes and Treatment Response in Fibrotic Hypersensitivity Pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31566307" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33798455" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37028940" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25412059" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Lung transplantation for hypersensitivity pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23515438" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Novel use of rituximab in hypersensitivity pneumonitis refractory to conventional treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24286447" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Rituximab in severe, treatment-refractory interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32971360" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Efficacy and safety of rituximab in patients with chronic hypersensitivity pneumonitis (cHP): A retrospective, multicentric, observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30126802" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Hypersensitivity pneumonitis: Antigen diversity and disease implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15121492" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16061708" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Chronic bird fancier's lung: histopathological and clinical correlation. An application of the 2002 ATS/ERS consensus classification of the idiopathic interstitial pneumonias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17641377" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Chronic hypersensitivity pneumonitis: CT features comparison with pathologic evidence of fibrosis and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28223152" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Pathologic Findings and Prognosis in a Large Prospective Cohort of Chronic Hypersensitivity Pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35273032" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28883091" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22586007" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A multidimensional index and staging system for idiopathic pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24114524" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Predicting survival across chronic interstitial lung disease: the ILD-GAP model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21412103" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Serial high-resolution computed tomography findings of acute and chronic hypersensitivity pneumonitis induced by avian antigen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22466512" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Chronic hypersensitivity pneumonitis: high resolution computed tomography patterns and pulmonary function indices as prognostic determinants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23392130" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28513215" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Presence of Air Trapping and Mosaic Attenuation on Chest Computed Tomography Predicts Survival in Chronic Hypersensitivity Pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18403660" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : High-resolution CT findings of parenchymal fibrosis correlate with prognosis in hypersensitivity pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28687910" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : CT findings associated with survival in chronic hypersensitivity pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30243979" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Hypersensitivity Pneumonitis: Radiologic Phenotypes Are Associated With Distinct Survival Time and Pulmonary Function Trajectory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26836921" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Chronic Hypersensitivity Pneumonitis With a Usual Interstitial Pneumonia-Like Pattern: Correlation Between Histopathologic and Clinical Findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28130610" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Automated computer-based CT stratification as a predictor of outcome in hypersensitivity pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22258419" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Pulmonary hypertension in chronic hypersensitivity pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24743965" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A haemodynamic study of pulmonary hypertension in chronic hypersensitivity pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8317802" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Farmer's lung. Long-term outcome and lack of predictive value of bronchoalveolar lavage fibrosing factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8466111" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Recovery of pulmonary function in farmer's lung. A five-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9311500" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Long-term outcome of pulmonary function in farmer's lung: a 14 year follow-up with matched controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9700147" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Long-term risk of emphysema in patients with farmer's lung and matched control farmers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3144636" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Hypersensitivity pneumonitis: correlation of cellular and immunologic changes with clinical phases of disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1192851" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Incidence of serum precipitins against organic-dust antigens in different populations by counterimmunoelectrophoresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4971361" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Farmer's lung. A clinical, radiographic, functional, and serological correlation of acute and chronic stages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1928962" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Bronchoalveolar mast cells in normal farmers and subjects with farmer's lung. Diagnostic, prognostic, and physiologic significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3942447" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Relationship among antigen contact, alveolitis, and clinical status in farmer's lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2107243" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Clinical and serologic follow-up of four children and five adults with bird-fancier's lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8372179" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Subacute and chronic bird breeder hypersensitivity pneumonitis: sequential evaluation with CT and correlation with lung function tests and bronchoalveolar lavage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8317813" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Mortality in Mexican patients with chronic pigeon breeder's lung compared with those with usual interstitial pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1414806" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Chronic hypersensitivity pneumonitis: use of CT in diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4231667" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Pigeon breeders' disease. A clinical study of a hypersensitivity pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/970736" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Bird breeder's hypersensitivity pneumonitis: progress studies of lung function after cessation of exposure to the provoking antigen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2602597" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Time of exposure as a prognostic factor in avian hypersensitivity pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3338304" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Longitudinal pulmonary function changes in pigeon breeders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2393316" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Clubbing in hypersensitivity pneumonitis. Its prevalence and possible prognostic role.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18689595" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Clinical predictors and histologic appearance of acute exacerbations in chronic hypersensitivity pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12839317" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Clinical features of recurrent and insidious chronic bird fancier's lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24999852" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Hypersensitivity pneumonitis in a cluster of sawmill workers: a 10-year follow-up of exposure, symptoms, and lung function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12519684" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : An outbreak of hypersensitivity pneumonitis at a metalworking plant: a longitudinal assessment of intervention effectiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27473679" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Hypersensitivity Pneumonitis Due to Metalworking Fluid Aerosols.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21978856" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Hypersensitivity pneumonitis and related conditions in the work environment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5201841" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Prevention of bagassosis by addition of propionic acid to sugar cane waste.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1615363" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Water-related lung diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2909203" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Hypersensitivity pneumonitis treated with an electrostatic dust filter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7336370" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Protective value of dust respirators in extrinsic allergic alveolitis: clinical assessment using inhalation provocation tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2909326" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Investigation on the protective value of breathing masks in farmer's lung using an inhalation provocation test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2467729" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : The long-term effect of a positive pressure respirator on the specific antibody response in pigeon breeders.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
